Benitec's Hepatitis C Drug Resurrected by Startup Company and Industry Veterans

Tacere Therapeutics, whose name is Italian for “to be silent,” was founded in July by two Benitec alums including former CEO Sara Cunningham Hall and ex-CFO Mike Catelani. The company plans to pursue both RNAi and small molecule therapeutics for hepatitis C.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.